Diasorin - Molecular
Biotechnology ResearchTexas, United States1001-5000 Employees
Diasorin’s molecular business, a combination of DiaSorin Molecular LLC and the Luminex Corporation Molecular products divisions, is now together as Diasorin. We specialize in the production of a comprehensive portfolio that includes targeted and syndromic molecular diagnostic products that are distributed globally to help laboratories streamline workflow and improve patient management. Our Simplexa® Direct kits for targeted molecular testing include products for congenital CMV, HSV 1 & 2, Flu A/B & RSV, COVID-19, COVID-19 & Flu A/B, Bordetella, VZV, Group A Strep, GBS, and C. difficile. Simplexa® products are designed for use on the LIAISON® MDX, a real-time PCR instrument. The instrument has the capability of running either an 8-well or 96-well disc, providing an ideal platform to accommodate low to high-volume testing needs. Our VERIGENE® panels for syndromic molecular testing include kits for bloodstream, respiratory, and gastrointestinal infections. The VERIGENE® System is a sample-to-answer system that enables clinicians to rapidly identify pathogens responsible for some of the most complex infectious diseases. Additionally, our menu includes over 65 primer pairs for laboratory developed tests. We proudly serve as a trusted vendor and partner to hospitals and reference laboratories, offering comprehensive sales, service, and support solutions. Our mission is to ensure that the right tests are delivered to the right patients at the right time, underscoring our commitment to enhancing healthcare outcomes.